Exploration of candidate genes responsible for esophageal squamous cell carcinoma (ESCC) pathogenesis may provide insight into the underlying signaling pathways to uncover novel therapeutic targets.
The ATR-CHK1 pathway plays a critical role as a replication checkpoint and is a promising target for emerging therapies.
With new variants and waning immunity occurring, especially in elderly and immunocompromised individuals, it is important to understand how to utilize the tools we have to prevent severe disease and death.
The Celigo Image Cytometer has been previously used for a wide range of immuno-oncology and immunotherapy studies, demonstrating the great utility of this instrument to assess the activity of cytotoxic immune cells against malignant cells of interest.
Sangivamycin is an unsuccessful anti-cancer drug candidate that has proven to be a potent inhibitor of multiple viruses. The authors of this study hypothesized that this compound would also be active against SARS-CoV-2.
Starting with a bioinformatics approach using publicly available databases, the authors were able to confirm that tissues from patients with lung adenocarcinoma had increased expression of BCCIP and that high expression levels of BCCIP were correlated with poor patient prognosis.
Cell-based treatments are life-saving therapies with the potential to offer cures for cancers and other diseases.
For the development of new drugs and the advancement of new cell therapies, pharmaceutical companies have recurred to cytotoxicity assays as a quick way to assess the viability of cell lines in response to an external stimulus.
The development of targeted molecular therapies is an increasingly popular approach to combat and overcome the limitations of conventional treatments.
A fundamental understanding of the molecular mechanisms responsible for the development and progression of RCC will be pivotal in developing next-generation treatment protocols to improve patient outcomes.
